Helios-Huaming BioPharma has synthesized new substituted salicylamide compounds acting as protein-arginine deiminase type-4 (PADI4) inhibitors reported to be useful for the treatment of cancer, rheumatoid arthritis and ischemia-reperfusion injury, among other disorders.